Source: http://feedproxy.google.com/~r/mnt/healthnews/~3/QNV6loHNlH4/222391.php
Thursday, 14 April 2011
iBioLaunch? Technology Versatility Confirmed In Peer-Reviewed Scientific Publications
iBio, Inc. (NYSE AMEX: IBIO) today announced release of results from a series of scientific studies of the breadth of product applicability of its iBioLaunch? technology. The results were published in a supplemental edition of the scientific journal Human Vaccines. The peer-reviewed scientific manuscripts describe both vaccine applications and monoclonal antibody applications of iBio's proprietary plant-based protein expression technology...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment